It is not recommended.
Clenbuterol hydrochloride is analyzed first.
Clenbuterol is a potent β2 agonist that improves airway spasm in bronchial asthma and wheezing bronchitis through the dilatation of bronchi effect, which restricted to used for asthma.
Clenbuterol has no effect on cough that due to non-airway spasm diseases such as cold, common bronchitis and pneumonia. In case of asthma, the efficacy and safety of clenbuterol determines that it is not a good choice among bronchodilators.
For example, atomized inhalation medicine of the similar pharmaceutical ingredients: almeterol and formoterol, have a faster and safer onset of action. In the United States, the FDA has not approved clenbuterol for human use due to its side effects.
Another ingredient is Ambroxol Hydrochloride.
This is a expectorant drug. First of all, the process of expelling dust, bacteria and viruses from sputum by coughing is a self-protective mechanism of the body and parents should not worry too much about it.
However, on the one hand the effectiveness of ambroxol is uncertain, and its expectorant effect is not confirmed by clinical results, so that it still not approved for marketing by the FDA.
There are also serious adverse reactions, and in 2016 the European Medicines Agency has specifically updated safety information regarding its severe allergic reactions and severe skin damage reactions (SCARs).
The American Academy of Pediatrics does not recommend the administration of expectorant drugs for children under 4 years of age, and the UK and Canada do not recommend them for children under 6 years of age.
The European Medicines Agency, the birthplace of this drug, also does not recommend it for use in children under 2 years of age, and it should only be applied in children 2-6 years of age with medical advice.
The European Medicines guidelines explicitly state that, considering that there is no benefit of ambroxol and clenbuterol hydrochloride and that there are important safety risks associated with the use of it, “in all age groups of patients with acute and chronic respiratory disease The benefit/risk ratio was negative in all age groups”.
